Healthcare Takes A Big Step Forward With The Help of A.I.

To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

Marc Began Biography and Net Worth

VP of Abiomed

Mr. Marc Began joined Abiomed in June 2018 and serves as vice president, general counsel, and secretary responsible for leading the company’s legal and compliance functions worldwide. Mr. Began has worked as a lawyer for more than 20 years, supporting various sectors of the life sciences industry, including pharmaceuticals, medical devices, and biotechnology. He joined Abiomed from Boehringer Ingelheim where he was vice president of intellectual property responsible for medical device, pharmaceutical, and biologic intellectual property issues.

Before joining Boehringer Ingelheim, Mr. Began held various positions of increasing responsibility at Novo Nordisk during a 15-year period. As assistant general counsel, he oversaw complex litigation matters. He also supported strategic transactions and business development. Prior to that, as assistant chief IP counsel, he managed global patent portfolios and enforcement strategy. Before joining Novo Nordisk, Mr. Began was an associate at the law firms of Sullivan & Cromwell and White & Case in New York where he handled a broad range of legal matters, including litigation, intellectual property, corporate transactions, regulatory and compliance.

Mr. Began earned a Juris Doctor degree from Albany Law School at Union University and holds a Bachelor of Science degree in mechanical engineering from Rensselaer Polytechnic Institute. He is also a licensed professional engineer and previously practiced engineering with the New York State Department of Environmental Conservation.

What is Marc A. Began's net worth?: The estimated net worth of Marc A. Began is at least $5.25 million as of November 4th, 2022. Mr. Began owns 13,785 shares of Abiomed stock worth more than $5,252,361 as of December 19th. This net worth estimate does not reflect any other assets that Mr. Began may own. Additionally, Mr. Began receives an annual salary of $818,640.00 as VP at Abiomed. Learn More about Marc A. Began's net worth.
How old is Marc A. Began?: Mr. Began is currently 56 years old. There are 5 older executives and no younger executives at Abiomed. The oldest executive at Abiomed is Dr. David M. Weber Ph.D., Scientific & Technology Advisor, who is 62 years old. Learn More on Marc A. Began's age.
What is Marc A. Began's salary?: As the VP of Abiomed, Inc., Mr. Began earns $818,640.00 per year. There are 3 executives that earn more than Mr. Began. The highest earning executive at Abiomed is Mr. Michael R. Minogue, Chairman, CEO & Pres, who commands a salary of $3,040,000.00 per year. Learn More on Marc A. Began's salary.
How do I contact Marc A. Began?: The corporate mailing address for Mr. Began and other Abiomed executives is 22 CHERRY HILL DR, DANVERS MA, 01923. Abiomed can also be reached via phone at (978) 646-1400 and via email at [email protected]. Learn More on Marc A. Began's contact information.
Has Marc A. Began been buying or selling shares of Abiomed?: Marc A. Began has not been actively trading shares of Abiomed during the last quarter. Most recently, Marc A. Began sold 2,000 shares of the business's stock in a transaction on Friday, November 4th. The shares were sold at an average price of $373.71, for a transaction totalling $747,420.00. Following the completion of the sale, the vice president now directly owns 13,785 shares of the company's stock, valued at $5,151,592.35. Learn More on Marc A. Began's trading history.
Who are Abiomed's active insiders?: Abiomed's insider roster includes Marc Began (VP), Andrew Greenfield (VP), Michael Minogue (CEO), Michael Minogue (CEO), Dorothy Puhy (Director), Joseph Riccelli, Sr. (CEO), Martin Sutter (Director), Paul Thomas (Director), Todd Trapp (CFO), David Weber (COO), and Magdalena Yesil (Director). Learn More on Abiomed's active insiders.

Marc A. Began Insider Trading History at Abiomed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/4/2022	Sell	2,000	$373.71	$747,420.00	13,785
8/29/2022	Sell	500	$255.95	$127,975.00	15,785

Marc A. Began Buying and Selling Activity at Abiomed

Abiomed Company Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Today's Range

Now: $381.02

$381.02

50 Day Range

MA: $380.55

$377.20

$381.30

2 Week Range

Now: $381.02

$219.85

$381.99

Volume

258 shs

Average Volume

611,028 shs

Market Capitalization

$17.18 billion

P/E Ratio

65.47

Dividend Yield

N/A

Beta

1.4

Healthcare Takes A Big Step Forward With The Help of A.I.

From Wall Street Star | Ad